Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children’s Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. Hettmer S, Linardic CM, Kelsey A, Rudzinski ER, Vokuhl C, Selfe J, Ruhen O, Shern JF, Khan J, Kovach AR, Lupo PJ, Gatz SA, Schäfer BW, Volchenboum S, Minard-Colin V, Koscielniak E, Hawkins DS, Bisogno G, Sparber-Sauer M, Venkatramani R, Merks JHM, Shipley J. Eur J Cancer. 2022 Jul 11;172:367-386. doi: 10.1016/j.ejca.2022.05.036. Online ahead of print. PMID: 35839732 Review.
Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children’s Oncology Group. Crane JN, Xue W, Qumseya A, Gao Z, Arndt CAS, Donaldson SS, Harrison DJ, Hawkins DS, Linardic CM, Mascarenhas L, Meyer WH, Rodeberg DA, Rudzinski ER, Shulkin BL, Walterhouse DO, Venkatramani R, Weiss AR. Pediatr Blood Cancer. 2022 Jun;69(6):e29644. doi: 10.1002/pbc.29644. Epub 2022 Mar 6. PMID: 35253352 Review.
Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence. Li JJ, Kovach AR, DeMonia M, Slemmons KK, Oristian KM, Chen C, Linardic CM. Sci Rep. 2021 Aug 13;11(1):16505. doi: 10.1038/s41598-021-95355-2. PMID: 34389744 Free PMC article.
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. Shern JF, Selfe J, Izquierdo E, Patidar R, Chou HC, Song YK, Yohe ME, Sindiri S, Wei J, Wen X, Rudzinski ER, Barkauskas DA, Lo T, Hall D, Linardic CM, Hughes D, Jamal S, Jenney M, Chisholm J, Brown R, Jones K, Hicks B, Angelini P, George S, Chesler L, Hubank M, Kelsey A, Gatz SA, Skapek SX, Hawkins DS, Shipley JM, Khan J. J Clin Oncol. 2021 Sep 10;39(26):2859-2871. doi: 10.1200/JCO.20.03060. Epub 2021 Jun 24. PMID: 34166060
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. Pacenta HL, Allen-Rhoades W, Langenau D, Houghton PJ, Keller C, Heske CM, Deel MD, Linardic CM, Shern JF, Stewart E, Turpin B, Harrison DJ, Khan J, Mascarenhas L, Skapek SX, Meyer WH, Hawkins DS, Chen EY, Amatruda JF, Hingorani P, Laetsch TW. J Clin Med. 2021 Apr 1;10(7):1416. doi: 10.3390/jcm10071416. PMID: 33915882 Free PMC article. Review.
Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target. Shields CE, Potlapalli S, Cuya-Smith SM, Chappell SK, Chen D, Martinez D, Pogoriler J, Rathi KS, Patel SA, Oristian KM, Linardic CM, Maris JM, Haynes KA, Schnepp RW. Mol Oncol. 2021 Aug;15(8):2156-2171. doi: 10.1002/1878-0261.12914. Epub 2021 Mar 27. PMID: 33523558 Free PMC article.
A method to culture human alveolar rhabdomyosarcoma cell lines as rhabdospheres demonstrates an enrichment in stemness and Notch signaling. Slemmons KK, Deel MD, Lin YT, Oristian KM, Kuprasertkul N, Genadry KC, Chen PH, Chi JT, Linardic CM. Biol Open. 2021 Feb 9;10(2):bio050211. doi: 10.1242/bio.050211. PMID: 33372065 Free PMC article.
Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children’s Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Rudzinski ER, Kelsey A, Vokuhl C, Linardic CM, Shipley J, Hettmer S, Koscielniak E, Hawkins DS, Bisogno G. Pediatr Blood Cancer. 2021 Mar;68(3):e28798. doi: 10.1002/pbc.28798. Epub 2020 Dec 11. PMID: 33306276 Review.
The third international meeting on genetic disorders in the RAS/MAPK pathway: towards a therapeutic approach. Korf B, Ahmadian R, Allanson J, Aoki Y, Bakker A, Wright EB, Denger B, Elgersma Y, Gelb BD, Gripp KW, Kerr B, Kontaridis M, Lazaro C, Linardic C, Lozano R, MacRae CA, Messiaen L, Mulero-Navarro S, Neel B, Plotkin S, Rauen KA, Roberts A, Silva AJ, Sittampalam SG, Zhang C, Schoyer L. Am J Med Genet A. 2015 Aug;167A(8):1741-6. doi: 10.1002/ajmg.a.37089. Epub 2015 Apr 21.
Asparaginase-Induced Hypertriglyceridemia Presenting as Pseudohyponatremia during Leukemia Treatment. Hinson A, Newbern D, Linardic CM. Case Rep Pediatr. 2014;2014:635740. doi: 10.1155/2014/635740. Epub 2014 Oct 27.
Rhabdomyosarcoma: current challenges and their implications for developing therapies. Hettmer S, Li Z, Billin AN, Barr FG, Cornelison DD, Ehrlich AR, Guttridge DC, Hayes-Jordan A, Helman LJ, Houghton PJ, Khan J, Langenau DM, Linardic CM, Pal R, Partridge TA, Pavlath GK, Rota R, Schäfer BW, Shipley J, Stillman B, Wexler LH, Wagers AJ, Keller C. Cold Spring Harb Perspect Med. 2014 Nov 3;4(11):a025650. doi: 10.1101/cshperspect.a025650. Review.
Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. Crose LE, Galindo KA, Kephart JG, Chen C, Fitamant J, Bardeesy N, Bentley RC, Galindo RL, Chi JT, Linardic CM. J Clin Invest. 2014 Jan;124(1):285-96. doi: 10.1172/JCI67087. Epub 2013 Dec 16.
RAS and ROS in rhabdomyosarcoma. Zhang M, Linardic CM, Kirsch DG. Cancer Cell. 2013 Dec 9;24(6):689-91. doi: 10.1016/j.ccr.2013.11.015.
Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells. Blum JM, Añó L, Li Z, Van Mater D, Bennett BD, Sachdeva M, Lagutina I, Zhang M, Mito JK, Dodd LG, Cardona DM, Dodd RD, Williams N, Ma Y, Lepper C, Linardic CM, Mukherjee S, Grosveld GC, Fan CM, Kirsch DG. Cell Rep. 2013 Nov 27;5(4):933-40. doi: 10.1016/j.celrep.2013.10.020. Epub 2013 Nov 14.
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Hinson AR, Jones R, Crose LE, Belyea BC, Barr FG, Linardic CM. Front Oncol. 2013 Jul 17;3:183. doi: 10.3389/fonc.2013.00183. eCollection 2013.
Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors. Chadalapaka G, Jutooru I, Sreevalsan S, Pathi S, Kim K, Chen C, Crose L, Linardic C, Safe S. Int J Cancer. 2013 Feb 15;132(4):795-806. doi: 10.1002/ijc.27730. Epub 2012 Aug 3. Erratum in: Int J Cancer. 2015 Sep 15;137(6):E9.
FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, Linardic CM. Clin Cancer Res. 2012 Jul 15;18(14):3780-90. doi: 10.1158/1078-0432.CCR-10-3063. Epub 2012 May 30.
In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Ignatius MS, Chen E, Elpek NM, Fuller AZ, Tenente IM, Clagg R, Liu S, Blackburn JS, Linardic CM, Rosenberg AE, Nielsen PG, Mempel TR, Langenau DM. Cancer Cell. 2012 May 15;21(5):680-93. doi: 10.1016/j.ccr.2012.03.043.
Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Belyea B, Kephart JG, Blum J, Kirsch DG, Linardic CM. Sarcoma. 2012;2012:406239. doi: 10.1155/2012/406239. Epub 2012 Apr 30.
Recurrent inflammatory myofibroblastic tumor of the heart. Andersen ND, DiBernardo LR, Linardic CM, Camitta MG, Lodge AJ. Circulation. 2012 May 15;125(19):2379-81. doi: 10.1161/CIRCULATIONAHA.111.066191.
Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis. Belyea BC, Naini S, Bentley RC, Linardic CM. Clin Cancer Res. 2011 Dec 1;17(23):7324-36. doi: 10.1158/1078-0432.CCR-11-1004. Epub 2011 Sep 23.
Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma. Crose LE, Linardic CM. Sarcoma. 2011;2011:756982. doi: 10.1155/2011/756982. Epub 2011 Jan 2.
Local therapy for rhabdomyosarcoma of the hands and feet: is amputation necessary? A report from the Children’s Oncology Group. La TH, Wolden SL, Su Z, Linardic C, Randall RL, Hawkins DS, Donaldson SS. Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):206-12. doi: 10.1016/j.ijrobp.2010.01.053. Epub 2010 Jun 18.
Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, Linardic CM. Cancer Res. 2008 Dec 1;68(23):9583-8. doi: 10.1158/0008-5472.CAN-07-6178.
PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Linardic CM. Cancer Lett. 2008 Oct 18;270(1):10-8. doi: 10.1016/j.canlet.2008.03.035. Epub 2008 May 23. Review.
Genetic modeling of Ras-induced human rhabdomyosarcoma. Linardic CM, Counter CM. Methods Enzymol. 2008;438:419-27. doi: 10.1016/S0076-6879(07)38028-2.
The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Linardic CM, Naini S, Herndon JE 2nd, Kesserwan C, Qualman SJ, Counter CM. Cancer Res. 2007 Jul 15;67(14):6691-9.
A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Kendall SD, Linardic CM, Adam SJ, Counter CM. Cancer Res. 2005 Nov 1;65(21):9824-8.
Genetic modeling of human rhabdomyosarcoma. Linardic CM, Downie DL, Qualman S, Bentley RC, Counter CM. Cancer Res. 2005 Jun 1;65(11):4490-5.
Rescue of an hTERT mutant defective in telomere elongation by fusion with hPot1. Armbruster BN, Linardic CM, Veldman T, Bansal NP, Downie DL, Counter CM. Mol Cell Biol. 2004 Apr;24(8):3552-61
Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT. Cancer Res. 2003 Dec 1;63(23):8451-60.
Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin. Fang Y, Linardic CM, Richardson DA, Cai W, Behforouz M, Abraham RT. Mol Cancer Ther. 2003 Jun;2(6):517-26.
Myelodysplasia as masquerader: A woman with hypereosinophilic syndrome and twelve years of “chronic ITP”. Linardic CM, Gong JZ, Rosoff PM. Med Pediatr Oncol. 2002 Aug;39(2):137-8.
